MAP2K7 and metastatic melanoma: This was a phase 1 clinical study in which V600 BRAF mutant metastatic melanoma patients, who were receiving concurrent treatment using the standard BRAF/MEK inhibitor combination of dabrafenib and trametinib, received intravenous infusions of GD2-iCAR-PBT products.